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Background and Purpose: A carboxy-O-methyl transferase inhibitor entacapone has been introduced as an 
adjuvant drug for Parkinson disease (PD) patients. Although clinical trials reported beneficial role of entacapone, a 
long-term trial over 3 years failed to show significant effect. The goals of this study were to evaluate the clinical 
benefit and the efficacy of entacapone in an open clinical practice.
Methods: After the completion of a double-blind placebo-controlled entacapone study, 149 patients from 4 
centers were included. Antiparkinsonian medications were optimized by the judgment of the neurologists in charge. 
The clinical global impression (CGI) scale was obtained at 6 months and 1 year after the initiation of entacapone 
treatment.
Results: Of the 149 patients, 117 patients chose to try entacapone in an open-label fashion. Sixty-nine (59%) 
patients completed the 1-year trial. Twenty-nine patients discontinued entacpaone before 6 months, and 19 between 
6 months and 1 year during trial. Twelve patients out of 48 patients discontinued entacapone because of its poor 
efficacy. The CGI scale was 3.9 (±1.5) at the beginning of the trial, 4.3 (±1.1) at 6 month, and 3.8 (±1.3) at 1 year, 
respectively. The CGI scale of those who discontinued between 6 month and 1 year was 3.4 (±1.7), which was 
worse, but insignificantly, than that of the continuer.
Discussion: The dropout at 1 year of our study was very high at 41%. Even though entacapone is indicated for 
advanced PD patients with motor fluctuation, the fluctuators commonly have dyskinesia and mental symptoms, which 
can become more troublesome with entacapone. In the patients with advanced PD, the clinical efficacy and side 
effects should be carefully considered in a long-term use of entacapone.
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INTRODUCTION
A carboxy-O-methyl transferase inhibitor (COMT 
inhibitor) entacapone (COMTAN
®) was introduced as 
an adjuvant drug for the patients with Parkinson disease 
(PD). It has been known to delay metabolism of levo-
dopa without affecting the peak plasma concentration or 
time to reach the peak concentration, which prolongs the 
duration of action of exogenous levodopa and its bio-
availability. However, the extent of clinical benefit of 
entacapone needs further clarification.
Several clinical trials over 1 or 6 months duration 
reported increased “on” time, which was considered Ahn TB, et al. Entacapone in Advanced Parkinson Disease
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Figure 1. Flow diagram shows the number of patients 
remained at 6 months and 1 year of the trial. Other reasons 
for discontinuation of entacapone are described in the text.
useful in case of wearing-off in advanced PD.
1-3 On the 
contrary, Unified Parkinson disease Rating Scale (UPDRS) 
scores were not improved in a 3-year trial of entacapone.
4 
Moreover, Fenelon et al’s 3-month study failed to show 
significant change in ‘on’ time and ‘off’ time.
5  Their 
argument for the effectiveness of entacapone was based 
on the improvement of UPDRS part IV item 39 and 
investigator’s global assessment of change.
In Korea, our group conducted a multicenter rando-
mized double-blind placebo-controlled entacapone study 
in PD patients with motor fluctuation.
6 The study demon-
strated that 1) entacapone is a safe and well-tolerated 
drug, 2) although the duration of ‘on’ and ‘off’ time 
were not significantly changed, entacapone showed an 
overall significant beneficial effect in the PD patients 
with wearing-off phenomenon. 
After the completion of the study, patients were given 
the choice of prescribing entacapone free of charge. The 
goals of this open-label study were to evaluate 1) the 
clinical benefit of entacapone under the usual circum-
stances of outpatient clinic without the restriction of a 
clinical trial, and 2) the efficacy of entacapone in a more 
prolonged period than typical 3 months clinical study 
duration. We report our experience of entacapone in an 
open-label trial over 1 year, which showed the limited 
role of entacapone as an adjuvant therapy in the patients 
with advanced PD.
MATERIALS AND METHODS
The multicenter double-blind placebo-controlled enta-
capone study included 197 parkinsonian patients from 5 
centers.
6 Inclusion criteria were 1) PD meeting the 
diagnostic criteria of UK PD Brain Bank, 2) age 
between 30-80 years old, 3) Hoehn and Yahr stage (HY 
stage) at ‘on’ time between 2 and 4, 4) ‘off’ duration 
longer than 2 hours per day. The study was approved by 
Institutional Review Boards. 
After completion of the 8 weeks study, patients were 
given the choice of prescribing entacapone free of charge. 
Of the five centers that participated in the mother study, 
4 centers joined in this study. Entacapone was adjusted 
according to the individual needs from 100 mg to 200 mg 
per dosing. Antiparkinsonian medications were optimized 
by the judgment of the neurologists in charge. Data on 
age, sex, duration of disease and levodopa treatment, and 
HY stage were collected. The clinical global impression 
(CGI) scale (1-7: No change=4, much worsened=1, 
much improved=7) was obtained by the investigators at 
base line, 6 month and 1 year after treatment.
7 Side 
effect profiles and reasons for drug discontinuation were 
followed up over 1 year.
 
RESULTS
The joining 4 centers had 149 participants who com-
pleted the preceding double-blind study. Of the 149 
patients, 117 patients (male=48, female=69) chose to try 
entacapone in an open-label fashion (Fig. 1). Mean age 
(±SD) of the patients was 57.5 (±9.5) years. Mean 
duration of disease and levodopa treatment was 7.9 (±3.8) 
and 5.6 (±3.0) years respectively. HY stage at ‘on’ time 
was 2.3 (±0.5). Sixty-nine (59.0%) patients remained on 
entacapone therapy till the end of 1-year trial (Fig. 1). Journal of Clinical Neurology: Vol. 3, No. 2, 2007
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Dropout rate was similar in each center. Twenty-nine 
(24.8%) patients discontinued entacpaone before 6 months, 
and 19 (16.2%) between 6 months and 1 year during 
trial. Twelve patients (25%) out of 48 patients discon-
tinued entacapone because they felt entacapone was not 
effective. Other reasons for discontinuation of enta-
capone were aggravated dykinesia (5) and psychiatric 
symptoms (10), gastrointestinal side effects (5), other 
medical problems (3), yellow urine (2), peripheral edema 
(1), knee pain (1), and death (1). Eight patients were lost 
during follow-up. The exact reasons were unknown in 5 
patients. 
The CGI scale was 3.9 (±1.5) at the beginning of this 
open-label trial, 4.3 (±1.1) at 6 month and became worse 
3.8 (±1.3), respectively (p=0.004). The CGI scale of those 
who discontinued between 6 month and 1 year after enta-
capone treatment was 3.4 (±1.7), which was worse, but 
insignificantly, than that of the continuer (p=0.07). 
There were no significant differences in age, disease 
duration, and levodopa treatment duration between the 
patients who completed 1-year trial and those who dis-
continued. HY stage at the beginning time of trial was 
more advanced in those who discontinued than those 
who completed an open trial (2.4 versus 2.2; p=0.019).
DISCUSSION
It may be assumed that patients who entered into this 
open-label study were getting benefit from entacapone 
and that patients who did not were not getting benefit 
or had side effects from entacapone. However, the drop-
out rate is very high up to 41% at 1 year of our study. 
The reasons for discontinuations were no clinical benefit 
in 25%, side effects in 48%, and unknown in 17%. 
As entacapone was given free of charge in our study, 
financial problem was not the reason for discontinuation. 
This very high discontinuation rate is similar to that of 
Larsen et al’s 3-year open labeled study which reported 
discontinuation of entacapone in up to 40.9% of the 
patients enrolled.
4  We also found the holistic negative 
opinion on the effectiveness of entacapone (worsened 
CGI scale at 1 year), even in those who continued the 
medication. Although various factors such as the change 
in the other antiparkinsonian medication and progression 
of PD could be assumed as the reason why CGI became 
worse even in the continuer, they could not be answered 
in this study. Another possibility is that entacapone 
could not meet the high expectation of these advanced 
PD patients with multiple problems.
The weak point of this study may be that we did not 
evaluate the objective parameters such as duration of “on” 
and “off” time and changes of levodopa dose. However, 
although patients may be more critical or more demanding 
of drug efficacy than the investigators are, we believe 
subjective satisfaction on the part of patients is an 
important measure of drug efficacy in antiparkinsonian 
medications.
Even though entacapone is primarily indicated for 
advanced PD patients with motor fluctuation, fluctuators 
commonly have dyskinesia and mental symptoms, which 
can be more troublesome with entacapone. It may be 
partly supported by the data that disease severity by HY 
stage at the beginning of entacapone trial was more 
advanced in those who discontinued (2.2 versus 2.4; 
p=0.019). 
It should be further evaluated whether the efficacy 
and side effects of entacapone could meet the needs of 
the patients with more advanced PD in long-term use. 
Rather, as the daily levodopa dose reduction was com-
monly reported in the previous long-term entacapone 
studies without significant change in UPDRS, enta-
capone may be more helpful in early stages of PD with 
emerging motor complication, in which ‘wearing off’ 
without significant dyskinesia is a predominant feature 
and levodopa dose is still small.
2,4
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